Loading
A ready-made antibody that pulls T cells onto myeloma cells produced responses in 63% of patients after a median of five prior therapies, without the wait for cell manufacturing.
MajesTEC-1 was a phase 1/2 single-arm study of teclistamab, a BCMA x CD3 bispecific T-cell engager given subcutaneously weekly after step-up dosing, in 165 patients with relapsed or refractory multiple myeloma who were triple-class exposed (median five prior lines). The overall response rate was 63%, with complete response or better in 39.4%; median duration of response was 18.4 months and median PFS 11.3 months. Cytokine release syndrome occurred in 72% (almost all grade 1-2) and neurotoxicity in about 14.5%, but infections were frequent (grade 3-4 in about 45%) and hypogammaglobulinaemia was near universal. Teclistamab received accelerated approval in 2022, the first bispecific for myeloma.
Teclistamab showed that an off-the-shelf bispecific can approach CAR-T-like response rates in late myeloma, giving patients who cannot wait for or access cell therapy a real option. It also exposed the price: prolonged T-cell engagement causes profound immunosuppression, so infection prophylaxis and immunoglobulin replacement are now routine. Less frequent dosing after response is being adopted to reduce this burden.
Shares Talquetamab, Teclistamab, Relapsed or refractory multiple myeloma, Johnson & Johnson.
Shares BCMA-directed therapy → GPRC5D-directed therapy, Talquetamab, Relapsed or refractory multiple myeloma, Johnson & Johnson.
Shares MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Elranatamab, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares BCMA-directed therapy → GPRC5D-directed therapy, MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response, Talquetamab, Relapsed or refractory multiple myeloma.
Shares MajesTEC-1, Teclistamab, BCMA, T-cell engagers (bispecific).
Shares Talquetamab, Teclistamab, BCMA, Bispecific antibodies.
Shares Elranatamab, Teclistamab, Cytokine release syndrome (CRS), Relapsed or refractory multiple myeloma.
Shares Teclistamab, BCMA, Cytokine release syndrome (CRS), Johnson & Johnson.